Edition:
United Kingdom

Suven Life Sciences Ltd (SUVP.NS)

SUVP.NS on National Stock Exchange of India

188.55INR
11:26am BST
Change (% chg)

Rs7.85 (+4.34%)
Prev Close
Rs180.70
Open
Rs180.50
Day's High
Rs189.80
Day's Low
Rs180.05
Volume
515,507
Avg. Vol
568,033
52-wk High
Rs250.80
52-wk Low
Rs155.00

Chart for

About

Suven Life Sciences Limited is a bio-pharmaceutical company. The Company is engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company's segments include Manufacturing (CRAMS), which develops and produces bulk drugs and intermediates under contract manufacturing services; Services (DDDSS),... (more)

Overall

Beta: 1.04
Market Cap(Mil.): Rs23,407.25
Shares Outstanding(Mil.): 127.28
Dividend: 1.50
Yield (%): 0.83

Financials

  SUVP.NS Industry Sector
P/E (TTM): 32.01 28.56 32.59
EPS (TTM): 5.65 -- --
ROI: 11.33 13.05 12.60
ROE: 12.40 14.79 14.49

BRIEF-Suven Life Sciences ‍Secures Product Patents In India And South Korea​

* PATENTS CORRESPONDING TO NEW CHEMICAL ENTITIES FOR TREATMENT OF DISORDERS RELATED TO NEURODEGENERATIVE DISEASES Source text: http://bit.ly/2sDvu6P Further company coverage:

20 Feb 2018

BRIEF-Suven Life Sciences Secures Product Patents In Aripo, South Korea

* SUVEN LIFE SCIENCES - PATENTS FOR NCES FOR TREATING DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES; PATENTS VALID THROUGH 2033 AND 2034 Source text - http://bit.ly/2nnkGoi Further company coverage:

31 Jan 2018

BRIEF-India's Suven Life Sciences Dec-Qtr Net Profit Rises

* DEC QUARTER NET PROFIT 346 MILLION RUPEES VERSUS PROFIT 242.7 MILLION RUPEES YEAR AGO

30 Jan 2018

BRIEF-Suven Life Sciences Secures Product Patents In Canada, India

* SAYS PATENT CORRESPONDING TO NEW CHEMICAL ENTITIES (NCES) FOR TREATMENT OF DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES

21 Dec 2017

BRIEF-Suven Life Sciences Gets Product Patents In India, U.S.

* SAYS CO SECURES PRODUCT PATENTS IN INDIA AND USA Source text - http://bit.ly/2AtbqHG Further company coverage:

11 Dec 2017

BRIEF-India's Suven Life Sciences Secures Product Patents In Eurasia, Norway

* PATENTS CORRESPONDS TO NEW CHEMICAL ENTITIES (NCES) FOR TREATMENT OF DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES Source text - http://bit.ly/2AUMl7N Further company coverage:

06 Dec 2017

Earnings vs. Estimates